3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Phase 1/2
1
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
2
Lung Neoplasms
1
Lung Diseases
1
Interventions
Carboplatin
314
Paclitaxel
302
Cisplatin
250
Docetaxel
237
pembrolizumab
230
Gemcitabine
213
Pemetrexed
158
Capecitabine
147
Rituximab
144
Bevacizumab
142
Dexamethasone
125
Fluorouracil
120
Cyclophosphamide
102
Trastuzumab
100
Doxorubicin
96
Nivolumab
92
Prednisone
91
Oxaliplatin
89
atezolizumab
73
Leucovorin
71
durvalumab
69
130-nm albumin-bound paclitaxel
67
Injections
64
Lenalidomide
63
Irinotecan
60
Bortezomib
55
Letrozole
54
Topotecan
53
Fulvestrant
53
Drug Therapy
50
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
INDUSTRY
×
zipalertinib
×
Clear all
NCT07128199
2026-05-05
REZILIENT4
Taiho Oncology, Inc.
Phase 3
Active not recruiting
360 enrolled
NCT05973773
2026-03-10
REZILIENT3
Taiho Oncology, Inc.
Phase 3
Active not recruiting
285 enrolled